Clin2
NCT07067385Possibly a fitRecruiting

Personalized mRNA vaccine for advanced GI cancers

Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant TherapyGastrointestinal Tumors

Part of Cancer, Digestive system clinical trials.

This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
40 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have advanced stomach, colon, or other digestive cancer that has spread or come back, and standard treatments are no longer working.
  • You must have a tumor that can be sampled (via biopsy or surgery) for genetic testing.
  • Your overall health should be good enough to allow you to get up and take care of yourself (ECOG 0 or 1).
  • Your blood counts, liver, kidney, heart, and thyroid function must be within safe limits.
  • You have not had a previous cancer vaccine, cell therapy, or certain immune checkpoint drugs.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06019702Recruiting· Phase 1
Personalized mRNA vaccine for advanced digestive cancers

This trial tests a personalized mRNA vaccine designed to target unique markers on your cancer cells. The vaccine is made just for you based on genetic testing of your tumor. It is for people with advanced digestive system cancers who have run out of standard options.

Hangzhou, Zhejiang
NCT06026800Recruiting· Phase 1
Personalized mRNA vaccine plus standard treatment for advanced digestive cancers

This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.

Hangzhou, Zhejiang
NCT06026774Recruiting· Phase 1
Personalized mRNA Vaccine After Digestive Cancer Surgery

This trial tests a personalized mRNA vaccine designed to train your immune system to fight your specific cancer. It's for people who have just had surgery to remove a digestive system cancer (like pancreatic or colorectal) and will also receive standard chemotherapy after surgery.

Hangzhou, Zhejiang
NCT06888648Not yet recruiting· Phase 1/Phase 2
Personalized mRNA Vaccine for Advanced Pancreatic Cancer

This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.

Hangzhou, Zhejiang
NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors

This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.

Shanghai, Shanghai Municipality
NCT06141369Recruiting
Personalized mRNA vaccine for advanced endocrine tumors

This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.

Shanghai, Shanghai Municipality

Hear when a new Gastrointestinal Neoplasms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.